Migraine

DENVER — Improvements are needed in the process to secure funding for migraine research, Rami Burstein, PhD, said at the American Headache Society annual scientific meeting.

The FDA has issued a complete response letter to Axsome Therapeutics Inc., in which the agency declined to move forward with a new drug application for AXS-07, an acute treatment for migraine.

SEATTLE — Trudhesa was effective in treating migraines of varying severity, a speaker said at the 2022 American Academy of Neurology annual meeting.

In a noninferiority randomized trial, the antidepressants amitriptyline and venlafaxine significantly reduced the number of migraine attacks per month, according to researchers.

Pregnancies complicated by migraines are associated with adverse outcomes for both women and their babies, according to a presentation at The Pregnancy Meeting.

Commercial-stage bioelectronic medicine company electroCore Inc. announced its noninvasive vagus nerve stimulation intervention for migraine prevention reduced the number of monthly headache days.

Neuroscience specialty pharmaceutical company OWP Pharmaceuticals Inc. has partnered with Eversana, a provider of global services to the life sciences industry, to launch oral liquid formulations for treating neuroscience disorders.

The FDA has cleared an investigational new drug application for the start of a phase 2 study of TNX-1900, a nasal spray created to prevent migraine headaches.

Healio Neurology featured some of the major stories from the American Neurological Association Annual Meeting.

Many patients who experience migraine or headaches either hesitated or never sought medical care for their condition, according to data from two studies presented during the PAINWeek National Conference.